Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Completed No phase listed Observational

Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence

NCT02070575
View directory record Official record
Conditions
Prostate Cancer
Interventions
blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Not applicable Interventional

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

NCT00056654
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Leuprolide acetate
Drug
Lead sponsor
Abbott
Industry
Eligibility
Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
55
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Phase 1Phase 2 Interventional

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

NCT04060394
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Phase I and Phase II: LAE001/prednisone + afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 30, 2026, 1:35 PM EDT
Recruiting Phase 1 Interventional

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07244341
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Valemetostat, Darolutamide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
La Jolla, California • Boston, Massachusetts • Newton, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 1:35 PM EDT
Recruiting No phase listed Observational

Prostate Cancer Genetic Risk Evaluation and Screening Study

NCT05129605
View directory record Official record
Conditions
Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Interventions
Prostate cancer screening
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 74 Years · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Not applicable Interventional

Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy

NCT00042731
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lycopene, Multivitamin, Soy isoflavones
Dietary Supplement
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
Phoenix, Arizona • Tampa, Florida • Savannah, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 30, 2026, 1:35 PM EDT
Terminated Early Phase 1 Interventional

Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy

NCT00952666
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRUS-RALRP
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
35 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 30, 2026, 1:35 PM EDT
Active, not recruiting Phase 2 Interventional Results available

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

NCT00859781
View directory record Official record
Conditions
Prostate Cancer
Interventions
177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 1:35 PM EDT
Terminated No phase listed Observational

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer

NCT00379119
View directory record Official record
Conditions
Prostate Cancer
Interventions
diagnostic laboratory biomarker analysis, flow cytometry, physiologic testing, computed tomography
Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

NCT03686683
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
56
States / cities
Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

NCT02643303
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Durvalumab, Tremelimumab, Poly-ICLC
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 30, 2026, 1:35 PM EDT
Completed No phase listed Observational

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer

NCT00905086
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 30, 2026, 1:35 PM EDT
Not listed Phase 2 Interventional

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

NCT00218205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Epirubicin, Estramustine Phosphate, Celecoxib
Drug
Lead sponsor
Department of Veterans Affairs, New Jersey
Federal
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 30, 2026, 1:35 PM EDT
Recruiting Not applicable Interventional

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

NCT06496256
View directory record Official record
Conditions
Prostate Cancer
Interventions
Barrigel, Transrectal Ultrasound
Device
Lead sponsor
Palette Life Sciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Chandler, Arizona • Santa Barbara, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 1:35 PM EDT
Active, not recruiting Not applicable Interventional

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

NCT01617161
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton Beam Therapy, Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
13
States / cities
Jacksonville, Florida • Chicago, Illinois • College Park, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 1:35 PM EDT
Terminated Phase 2 Interventional Results available

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

NCT01450683
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer, Hormone-refractory Prostate Cancer, Metastatic Disease
Interventions
Itraconazole
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 30, 2026, 1:35 PM EDT
Recruiting Phase 3 Interventional

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277
View directory record Official record
Conditions
Prostate Cancer
Interventions
AAA817, ARPI, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
42
States / cities
Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

NCT05700669
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
Interventions
AsiDNA, Olaparib
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 1:35 PM EDT
Enrolling by invitation Not applicable Interventional

Genetic Education in BRCA Families

NCT03544983
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Web + Streamlined Telephone Genetic Information
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 30, 2026, 1:35 PM EDT
Recruiting Not applicable Interventional

A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)

NCT07535541
View directory record Official record
Conditions
Prostate Cancer, Hot Flashes
Interventions
VMS logging
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 30, 2026, 1:35 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

NCT04262154
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
Drug · Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Phase 2 Interventional

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

NCT00349557
View directory record Official record
Conditions
Prostate Cancer
Interventions
bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT)
Drug · Procedure
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Phase 1 Interventional

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

NCT01902251
View directory record Official record
Conditions
Prostate Cancer, Pharmacokinetics of Enzalutamide
Interventions
Enzalutamide tablet, Enzalutamide capsule
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Denver, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 30, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

NCT03261999
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Leuprolide Mesylate
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Homewood, Alabama • Tucson, Arizona • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 30, 2026, 1:35 PM EDT